Palatin Technologies, Inc - PTN.BC Logo
4c Cedar Brook Drive, Cranbury, NJ, 08512, US. TEL: 609-495-2200 http://www.palatin.com
Last SaleNet Change% ChangeVolumeLast Updated
$0.280.001.82285,48111/20/09 3:58 PM ET


Profile News

Security TypeCommon StockSpecialist076
IndustryHealth Services, Pharmaceuticals, and Medical DiagnosticsTrading Post2
Primary ExchangeNYSE AmexSEC Filings

Description

Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products in development include PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure, including chronic heart failure and acute heart failure, as well as for the treatment of difficult-to-control hypertension, including dialysis patients with hypertension; Bremelanotide, a peptide melanocortin receptor agonist, for prevention of organ damage secondary to cardiac surgery and related indications; and PL-6983, a peptide melanocortin receptor agonists, for treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey.
Quote


Last Sale$0.28
(11/20/09)
Net Change0.00
% Change1.82
Previous Close$0.28
Today’s Open$0.27
Today’s High$0.28
Today’s Low$0.27
Volume285,481
52 Week High$0.48
52 Week Low$0.06
Chart


3mo | 6mo | 12mo | 24mo | 36mo | 48mo | 60mo
Click here to view the data behind the chart.

Fundamentals

P/E ratio -28.00 Short Interest 1,308,823
Earnings Per Share 0.00 Current yield N.A.
Shares Outstanding 96,172,000 Dividend Info
Market Cap 26,928,160


.BC, .LF  This issue is currently below the continued listing standards of the NYSE Amex, which can be viewed in the NYSE Amex Company Guide. A complete list of all non-compliant issues is also available.